Vanguard Group Inc Akero Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,704,411 shares of AKRO stock, worth $176 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,704,411
Previous 3,676,581
0.76%
Holding current value
$176 Million
Previous $105 Million
2.3%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding AKRO
# of Institutions
210Shares Held
74.3MCall Options Held
321KPut Options Held
558K-
Wellington Management Group LLP Boston, MA7.38MShares$350 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY6.86MShares$326 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$286 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$265 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$248 Million5.21% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.2B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...